about
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients.Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs.Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART.Mother-to-child transmission of TT virus: sequence analysis of non-coding region of TT virus in infected mother-infant pairs.Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients.Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy.The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.The introduction of the fusion inhibitors in the HAART-regimens.Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin.Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.Prevalence of type 2 diabetes mellitus and its predictive factors in Italy: a comparison between HIV-infected and uninfected subjects.In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders.Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters.Immunovirological improvement in partially HAART responder HIV-infected patients by monocyte adsorption apheresisEvolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective PressureOccurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antiviralsMonotherapy With Atazanavir as a Simplificati StrategyA case of HIV-associated fever of unknown origin: deficit of IL-1β antagonistic activity and resolution with monocyte–granulocyte apheresis
P50
Q33994281-3016EAC8-D638-4E7B-B43C-4FCEBF2FDDAEQ37176312-6FC47882-3A64-415A-8899-19112CC8F475Q38430411-139BCEB2-EACC-4500-BFAF-1A18BB69E48DQ39222831-48BAAEA8-2E08-4FCB-925D-B38DEFB6EDA4Q39955709-CFA685E5-EBB8-4AFA-AA49-1B4D909B4238Q40237283-C5BB8221-CF5C-4DA1-AF93-2589DFABC8D2Q40377822-4D3AD22F-3AE9-4A70-A1BB-7305FF46F131Q40401740-2EE021DA-FBA2-4513-94C5-5C074D5D67BCQ40482870-6DA947F6-C31D-42F0-A7A2-49F1892785A3Q40667760-46DE53EC-07AC-47C8-ADC6-623F42AF75B3Q40819897-104A9585-CE98-4F25-9C79-169E721A2399Q40856569-3B3BC758-AF96-4825-A6A2-25EBDC72CE67Q41634185-CEA19856-AA21-4BAF-AF13-CE1A9E43E40DQ42269060-5C996A5E-4CE1-4262-BEA5-9181C8C977E2Q42635997-965ECBB6-CD9C-4D31-BE49-33B4787E03D6Q42676088-133817F6-6D75-4FDF-8E45-9C9277035029Q42677372-FF442D25-488C-44F9-824F-3C275A95E87BQ42988991-D8468A64-384F-417C-A2DD-0864EDEE7C7DQ43757968-AFD491FC-D8D3-48D7-B153-02B925596606Q44367209-FE09EA3D-87BE-4DCE-87D2-99019AE1CCF5Q44726338-A228E738-6688-49DB-95E7-60FEBD226085Q44848448-073F50F6-586B-4CEC-B15B-EEDD6BB0C413Q44881138-955E962C-0F1A-4BBD-A625-AF727A3967CEQ45084307-B88B8B81-0E47-4B1D-9B75-6533D4018D7FQ45221045-38B92716-84FA-43B0-AFA0-BB7A55414FE1Q45221051-EDF41CFC-0EBE-4E9B-B556-AC72815E988AQ45340126-7E6007F1-82E6-4436-8B5A-CEB2C7C366FCQ46057921-17ECD324-5827-48CD-9CA4-081BB5F175E8Q46474201-441EFFBC-857F-40CE-B5AD-D83636D4074BQ46688412-270450F3-F393-44E1-9F8B-89969B4FA182Q46762721-357E8752-B883-4931-963D-84E4C878EC1CQ47294649-30345DDA-41BA-4AB5-A547-A56B394E26E7Q47296847-20DC8742-A9F7-4BD0-9D04-DAFF64D91D38Q51930284-C99F56A6-70DC-455F-9FDF-C974BADB9F12Q52012813-2277EEC8-0DEE-4705-B686-1DC2721D00ACQ57997583-BFBC9130-7B16-4E73-9266-4E8F14C53305Q58228924-77315196-D87F-4BC4-BCC5-FD7F2F3FA35CQ58290221-93165CE9-74EA-4ACD-AD4B-AA7C4E702F7CQ58290703-EAD8CA91-C564-49A7-9900-99F2531D3A82Q58291279-DB006377-BBD3-4B14-81D4-D62903E0C4B6
P50
description
researcher ORCID ID = 0000-0002-1938-7335
@en
wetenschapper
@nl
name
Hamid Hasson
@ast
Hamid Hasson
@en
Hamid Hasson
@es
Hamid Hasson
@nl
type
label
Hamid Hasson
@ast
Hamid Hasson
@en
Hamid Hasson
@es
Hamid Hasson
@nl
prefLabel
Hamid Hasson
@ast
Hamid Hasson
@en
Hamid Hasson
@es
Hamid Hasson
@nl
P106
P31
P496
0000-0002-1938-7335